VCC Clinical & Translational Research Symposium
Epigenetics and Cancer
Friday, November 8, 2013
Fletcher Allen Health Care
Carlo Croce, MD
Dr. Croce, a member of the National Academy of Sciences in the US and the Accademia Nazionale delle Scienze detta deiXL in Italy, has received almost every significant award for cancer research that one can earn. He was awarded two Outstanding Investigator awards from the National Cancer Institute, the Richard and Hinda Rosenthal Foundation Award and the GHA Clowes Memorial Award from the American Association for Cancer Research, the John Scott Award, the Robert J. and Claire Pasarow Foundation Cancer Award, the GM Cancer Research Foundation - Charles S. Mott Prize, the Scanno Prize for Medicine, the AACR-Pezcoller Award, the Raymond Bourgine Award and Gold Medal of Paris and President of the Republic Prize, the iwCLL Binet-Rai-Medal for Outstanding Contribution to CLL Research, the Henry M. Stratton Medal from the American Society of Hematology, the Albert Szent-Györgyi Prize for Progress in Cancer Research, the Leopold Griffuel Prize awarded by the French Association for Cancer Research, The Ernst W. Bertner Memorial Award, The University of Texas MD Anderson Cancer Center and most recently, an Elected Member of The American Academy of Arts and Sciences. He is principal investigator on seven federal research grants and has more than 875 peer-reviewed, published research papers.
Michael Cole, PhD
Dr. Cole received a BA in Physics from Ohio Northern University in 1973 and a PhD in Biophysics in 1978 from Johns Hopkins University. Following postdoctoral work in the Biology Department at Johns Hopkins, Dr Cole joined the faculty of the Department of Biochemistry at the St Louis University Medical School in 1980. In 1984, he moved to the faculty of the Department of Molecular Biology at Princeton University. Dr Cole joined the faculty of the Department of Pharmacology and Toxicology in the Dartmouth Medical School in 2003.
Kenneth Nephew, PhD
Dr. Nephew is the Director of Graduate Education and the Assistant Director of Basic Science Research at the Walther Cancer Institute. His research interests include cancer epigenetics, DNA methylation and chromatin remodeling, epigenetic therapy, and much more.
Xiaobing Shi, PhD
Dr. Shi's research lab focuses on the epigenetic regulation of chromatin and transcription. He is currently focusing on elucidating the roles of the PHD fingers present in the recently identified JmjC domain-containing KDMs in the regulation of chromatin dynamics. Recently he helped to develop a histone peptide array for a high-throughput screen to identify novel reader proteins that recognize distinct histone methylation.
Paula Vertino, PhD
Dr. Vertino received her PhD from the State University of New York in Buffalo, New York and completed her postdoctoral fellowship in oncology at the Johns Hopkins Oncology Center. She is a permanent member of the Cancer Etiology Study Section of the National Institutes of Health and a prominent leader at the Emory University Winship Cancer Institute.
Xiang-Jiao Yang, PhD
Since October 1997, Dr. Yang has been an independent investigator and a faculty member at the Department of Medicine, McGill University. Since the mid-1990s, he has investigated the molecular and biological functions of lysine acetyltransferases and deacetylases by use of molecular and genetic approaches.
Karen Glass, PhD
Dr. Glass' long-term goal is to study the molecular mechanisms controlling how genetic information is dynamically packaged into a higher order structure known as chromatin, to understand how epigenetic signalling regulates the packaging and regulates cellular functions, including gene transcription and replication. Furthermore, her studies are aimed to elucidate how disruption of these events is linked to the progression of diseases such as leukemia. To make unique and innovative contributions to the cancer biology of leukemia, she and her colleagues use in vitro biochemical, biophysical and structural biology studies in combination in vivo functional investigations using human progenitor blood cells and chromatin. These broad-spectrum combinatorial analysis are designed reveal new insights into the role of chromatin-binding complexes and protein-protein interactions involved in regulating gene expression in normal versus leukemic cells, translating the in vitro work to potential clinical relevance.
Kaleem Zaidi, PhD
Dr. Zaidi is a cancer cell biologist, whose work focuses on understanding epigenetic mechanisms that are compromised in human leukemia.With over 80 publications that include original research articles, and invited reviews and book chapters, he has extensive experience in the areas of cell & molecular biology and cancer research. Dr. Zaidi is a recipient of the AIMM Young Investigator Award, a research grant from American Cancer Society, is an associate editor for the Journal of Cellular Biochemistry, and serves as a reviewer for several academic journals. He is a member of the American Association for Cancer Research, and has served as a co-organizer for institutional, regional and national research conferences. Dr. Zaidi is also a Principal Investigator of an NCI-funded grant to study the role of microRNAs in human leukemia
Charles Brooks, events coordinator
Vermont Cancer Center
Courtyard at Given N-419
89 Beaumont Avenue
Burlington, VT 05405
Contact by Email
Last modified November 01 2013 02:48 PM